Advanced Accelerator Applications

NCT02230176

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

NCT02667457

99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis

NCT02677714

99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer

NCT03232580

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03724253

[68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

NCT04343885

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

NCT04443062

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

NCT04039516

Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy

NCT04903899

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma

NCT04837885

Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

NCT05150236

EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC

NCT04711135

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT05198479

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in

NCT04529044

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

NCT06783348

Radiopharmaceutical Treatment of Advanced Kidney Cancer